Efﬁcacy and Safety of Approved First-Line Tyrosine

Kinase Inhibitor Treatments in Metastatic Renal Cell

Carcinoma: A Network Meta-Analysis by Manz, Kirsi M. et al.
ORIGINAL RESEARCH
Efficacy and Safety of Approved First-Line Tyrosine
Kinase Inhibitor Treatments in Metastatic Renal Cell
Carcinoma: A Network Meta-Analysis
Kirsi M. Manz . Klaus Fenchel . Andreas Eilers . Jonathan Morgan .
Kirsten Wittling . Wolfram C. M. Dempke
Received: September 30, 2019
 The Author(s) 2019
ABSTRACT
Introduction: This network meta-analysis aims
to deliver an up-to-date, comprehensive efficacy
and toxicity comparison of the approved first-
line tyrosine kinase inhibitors (TKIs) for meta-
static renal cell carcinoma (mRCC) in order to
provide support for evidence-based treatment
decisions. Previous NMAs of first-line mRCC
treatments either predate the approval of all the
first-line TKIs currently available or do not
include evaluation of safety data for all
treatments.
Methods: We performed a systematic literature
review and network meta-analysis of phase II/III
randomised controlled trials (RCTs) assessing
approved first-line TKI therapies for mRCC. A
random effects model with a frequentist
approach was computed for progression-free
survival (PFS) data and for the proportion of
patients experiencing a maximum of grade 3 or
4 adverse events (AEs).
Results: The network meta-analysis of PFS
demonstrated no significant differences
between cabozantinib and either sunitinib
(50 mg 4/2), pazopanib or tivozanib. The net-
work meta-analysis indicated that in terms of
grade 3 and 4 AEs, tivozanib had the most
favourable safety profile and was associated
with significantly less risk of toxicity than the
other TKIs.
Conclusion: These network meta-analysis data
demonstrate that cabozantinib, sunitinib,
pazopanib and tivozanib do not significantly
differ in their efficacy, but tivozanib is associ-
ated with a more favourable safety profile in
terms of grade 3 or 4 toxicities. Consequently,
the relative toxicity of these first-line TKIs may
play a more significant role than efficacy com-
parisons in treatment decisions and in planning
future RCTs.
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Key Summary Points
Why carry out this study?
A network meta-analysis was performed,
evaluating approved first-line tyrosine
kinase inhibitors (TKIs) for metastatic
renal cell carcinoma (mRCC).
This provided an up-to-date,
comprehensive analysis of phase II/III
randomized controlled trial data.
What was learned from this study?
No significant efficacy differences between
approved first-line TKIs were observed.
Tivozanib ranked the most favourable in
the analysis of grade 3 and 4 adverse
events.
This produced indirect evidence to
support clinical decisions and planning of
future trials.
INTRODUCTION
The treatment of metastatic renal cell carci-
noma (mRCC) has evolved over the last decade
and now harbours several different drug classes
[cytokines, tyrosine kinase inhibitors (TKIs),
mammalian target of rapamycin inhibitors and
immune checkpoint inhibitors (ICIs, IOs)]
[1, 2]. European mRCC treatment guidelines
[European Association of Urology (EAU) and
European Society for Medical Oncology
(ESMO)] were updated in 2018/2019, with TKIs
recommended as the standard for treating
favourable International Metastatic RCC Data-
base Consortium (IMDC) risk-group patients,
but as optional first-line treatments (secondary
to ICIs as standard) in intermediate- or poor-risk
patients [1, 2]. Guidelines now include the fol-
lowing TKIs as first line: cabozantinib, pazopa-
nib, sorafenib, sunitinib and tivozanib [1, 2].
The first-line TKI options have varying potency
and selectivity for vascular endothelial growth
factor receptors (VEGFRs) [3, 4]. Pazopanib,
sorafenib, sunitinib and cabozantinib are con-
sidered multi-targeted TKIs because they inhibit
several tyrosine kinases, such as platelet-derived
growth factor receptor and c-KIT, in addition to
VEGFR, whereas tivozanib has been shown to
potently and selectively target all three VEGF
receptors [3, 4]. All approved first-line TKIs have
demonstrated anti-tumour activity, but it is
proposed that the off-target effects contribute to
differences between the toxicity profiles [1–4].
Examples of off-target toxicities include diar-
rhoea, fatigue and hand-foot syndrome,
whereas VEGF-associated toxicities include
hypertension and hypothyroidism [3, 4]. With
many TKIs available, and given the lack of head-
to-head randomised controlled trials (RCTs), it
is important to evaluate the relative efficacy and
toxicity of each TKI to support an evidence-
based approach to treatment. Two previous
network meta-analyses (NMAs) of first-line
mRCC treatments have been carried out: one
predates the approval of cabozantinib as a first-
line treatment; the other demonstrated that
there was no significant difference in progres-
sion-free survival (PFS) associated with several
first-line treatments, but this analysis did not
include safety profile data for all therapies
studied [5, 6]. Toxicity may be an important
differentiator between these treatments. This
NMA aims to provide an up-to-date, compre-
hensive efficacy and toxicity comparison
between each of the approved first-line TKIs for
mRCC.
METHODS
Systematic Literature Review
Methodology
We performed a systematic literature review and
NMA of phase II/III RCTs assessing approved
first-line TKI therapies for mRCC. PubMed,
ClinicalTrials.gov, Embase, Medline, the
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Cochrane Central Register of Controlled Trials,
Web of Science and conference abstracts from
the American Society of Clinical Oncology
(ASCO), ESMO and ASCO-Genitourinary were
searched independently by two authors (WD
and AE). Only English language publications
from database inception to 15 January 2019
were included. Search terms included: ran-
domised clinical trial; metastatic renal cell car-
cinoma; advanced renal cell carcinoma;
tyrosine kinase inhibitor; first-line; phase II
trial; phase III trial; immunotherapy; progres-
sion-free survival; adverse events. Results were
restricted to phase II and phase III RCTs. Bibli-
ographies of review articles and editorials were
manually searched. The literature review pro-
cess followed Preferred Reporting Items for
Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [7]: two authors (JM and
KF) independently evaluated data from eligible
studies, which were then checked by a third
author (KW), and any disagreements were
resolved by discussions moderated by a fourth
author (WD). A bias risk assessment was con-
ducted using The Cochrane Collaboration’s tool
[8]. All RCTs comparing a first-line TKI with
other TKIs, placebo or interferon-alfa (IFN-a; a
historic standard of care) were included; other
comparators were excluded. Additional exclu-
sion criteria included: non-randomised trials,
retrospective studies, second-line or later-line
studies, case reports and TKIs not approved for
first-line therapy.
The outcome measure used to evaluate effi-
cacy in the NMA was PFS, as first reported by the
study authors (i.e., either independent review
committee or investigator assessed). In some
instances, time-to-progression (TTP) data were
substituted as a close approximate. The toxicity
outcome measure used was the proportion of
patients experiencing a maximum of grade 3 or
4 adverse events (AEs). Contact with the study
authors was attempted (email and/or tele-
phone) to obtain missing information. In some
cases it was possible to derive missing informa-
tion from available data using formulae adapted
from Woods et al. (2010) and Altman and Bland
(2011) [9, 10].
Data collection for this work is based on
previously conducted studies and does not
contain any study with human participants or
animals performed by any of the authors. The
data are solely obtained from published studies.
Statistical Analysis
All statistical analyses were performed using R
software and the netmeta package [11, 12]. For
the network analyses, the treatment effect [log
(PFS hazard ratio)] and toxicity effect [log (rel-
ative risk of % patients experience grade 3 or 4
AE)], and estimates of the standard error of
each, were inputted into the model, using the
data are collated in Table 1. Network diagrams
were produced: the thickness of the connecting
lines represents the strength of evidence for a
treatment effect [11–13].
Weperformed anNMAusing a randomeffects
model with a frequentist approach [14, 15]. A
fixed effect model was tested but significant
heterogeneity was detected in the overall net-
work (Qtotal = 13.99, p = 0.0073), which could be
decomposed into considerable heterogeneity
between the designs (Qbetween = 12.00,
p = 0.0074) and non-significant heterogeneity
within the designs (Qwithin = 1.99, p = 0.1586). A
design consists of a pairwise comparison of two
treatments such as sorafenib vs. tivozanib.
Therefore, a random effects model was selected
over a fixed-effects model to account for this
potential heterogeneity (different study designs,
populations, treatment arms, etc.) [16].
Sources of inconsistency in the random
effects model were investigated by the genera-
tion of net heat plots: the colour-scale shading
of each box indicates whether the design was a
source of inconsistency (red) or supported other
evidence (blue), and the area of the grey boxes
indicates the contribution of direct-comparison
evidence and indirect evidence (given in the
columns) to the network estimate of a com-
parison (shown in the rows) [13].
Treatments were ranked by calculating
P scores using the netrank function of the net-
meta package [11, 17]. P scores measure the
extent of certainty that a treatment is better
than another treatment, averaged over all
competing treatments, while taking the preci-
sion into account [17].
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RESULTS
The systematic literature search identified 699
unique references, which, after review, revealed
12 that fitted the screening criteria (Fig. 1).
Table 1 presents the RCT data input into the
model and some key trial characteristics. The
RCTs directly comparing TKIs to either IFN-a or
placebo demonstrated significant improve-
ments in PFS [18–20], except for sorafenib ver-
sus IFN-a [21]. RCTs directly comparing TKIs to
one another demonstrated mixed results: some
demonstrated significant improvements in PFS
[22, 23] or established non-inferiority [24] while
others did not [25–30]. As data from two studies
were available in abstract form only, we were
unable to access their risk of bias. All other
studies included were open-label trials. We felt
that all studies were at low risk of attrition and
reporting bias.
For the efficacy NMA, we included all 12
studies with a total of 4306 patients (Fig. 2a),
and for the safety analysis, we included data for
all 12 studies with a total of 4243 patients
(Fig. 3a). The strength of evidence for the suni-
tinib (50 mg 2/1) dosing regimen was the
weakest in the NMA (Fig. 2a, 3a), perhaps
because of the small sample size (Table 1). The
NMA output data are tabulated in Appendix
Tables S1 and S2. The eligibility criteria for the
12 studies varied, for example the majority of
studies did not specify a Memorial Sloan Ket-
tering Cancer Center (MSKCC) prognostic
group as an entry criteria, except for three
studies that only enrolled patients with a
favourable or intermediate MSKCC risk score
[26–28] and one that enrolled patients of
intermediate or poor IMDC risk category [23].
These differences in eligibility criteria can be a
potential source of heterogeneity, which is
partially accounted for in the random effects
Fig. 1 PRISMA diagram
Adv Ther
model. When analysing for specific sources of
heterogeneity, the studies including only
favourable or intermediate MSKCC risk patients
[26–28] were not collectively found to be a sig-
nificant cause of inconsistency (Figs. 2d, 3d).
The net heat plots also show that these studies
contribute important indirect evidence to the
model. It was not possible to analyse the effect
of restrictive MSKCC eligibility criteria at the
other end of the prognostic risk spectrum in this
way because only one cabozantinib study that
used these criteria was included [23].
Figure 2b shows the NMA results of the
indirect efficacy comparison with placebo; the
confidence intervals demonstrate that
cabozantinib, sunitinib [standard regimen
(50 mg 4/2)], pazopanib, tivozanib and sor-
afenib treatments were significantly different
from placebo, whereas the alternative sunitinib
dosing regimens [50 mg 2/1 and 37.5 mg con-
tinuous daily dose (CDD)] were not. Cabozan-
tinib had the highest probability of being the
best treatment in terms of PFS (P score 0.9481),
followed by sunitinib, pazopanib and tivozanib
(P score 0.7411, 0.6914 and 0.5988, respec-
tively) (Table 2). When treatments were indi-
rectly compared with cabozantinib, it was clear
that there was no significant difference in PFS
Fig. 2 Network meta-analysis of PFS: a network diagram;
b forest plot, with placebo as the comparator. PFS
progression-free survival, HR hazard ratio, CI confidence
interval; c forest plot, with cabozantinib as the compara-
tor; d net heat plot. Red areas are related to inconsistency,
whereas blue areas support other evidence gained from the
network. The area of a grey box indicates the contribution
of the direct estimate of the pairwise comparison in the
column to a network estimate in a row
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between the first-line TKIs, with the exception
of sorafenib, which was associated with a sig-
nificantly shorter PFS (Fig. 2c). Figure 3b shows
the NMA toxicity results for the indirect com-
parison of first-line TKIs with cabozantinib: the
confidence intervals demonstrate that tivoza-
nib, placebo and IFN-a were associated with a
significantly lower likelihood of grade 3/4 AEs.
Calculation of P scores confirms that tivozanib
has a 92.6% probability of having the least
toxicity (Table 2). Indirect toxicity comparison
with tivozanib demonstrates that the grade 3/4
safety profile of tivozanib is significantly dif-
ferent from all other first-line TKIs (Fig. 3).
DISCUSSION
The therapeutic arsenal at hand to treat kidney
cancer patients is evolving rapidly with novel
IO-IO combinations (e.g., nivolumab plus ipili-
mumab—CheckMade-214 trial [33]) or IO-TKI
combinations (e.g., avelumab plus axitinib—
Javelin-101 trial [34]; pembrolizumab plus axi-
tinib—Keynote-426 trial [35]) now being
approved by the FDA and/or EMA as first-line
combination treatment strategies. These com-
binations have improved treatment outcome
dramatically with a significant overall survival
Fig. 3 Network meta-analysis of percentage grade 3 or 4
AEs: a network diagram; b forest plot, with cabozantinib
as the comparator. AE adverse event, RR relative risk, CI
confidence interval; c forest plot, with tivozanib as the
comparator; d net heat plot. Red areas are related to
inconsistency, whereas blue areas support other evidence
gained from the network. The area of a grey box indicates
the contribution of the direct estimate of the pairwise
comparison in the column to a network estimate in a row
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benefit (Keynote-426 and CheckMade-214).
However, the observed clinical benefit in these
trials was associated with increased grade 3/4
AEs: 75.8% for pembrolizumab/axitinib [35]
and 71.2% for avelumab/axitinib [34]. For the
IO-IO combination, grade 3 and 4 AEs were
reported to be 46% and 63%, respectively, with
a treatment discontinuation rate of 22% due to
adverse events [33], suggesting that there is still
a role for a single TKI treatment especially in
elderly and less fit patients; however, the opti-
mal TKIs for these patients remain unclear.
This NMA was conducted in an attempt to
provide a comprehensive comparison of the
efficacy and safety of approved first-line TKIs for
advanced and metastatic renal cell carcinoma.
The efficacy NMA P scores ranked the first-line
TKIs from highest probability of efficacy
downward as follows: cabozantinib, sunitinib
(50 mg 4/2); pazopanib and tivozanib, sunitinib
(37.5 mg CDD); sunitinib (50 mg 2/1), sor-
afenib. It is possible that the small sample size
influenced the sunitinib (50 mg 2/1) ranking
result. Cabozantinib had a 94.8% probability of
being the best treatment in terms of PFS; how-
ever, several other treatments also had
P scores[50%, and the confidence intervals
demonstrate that no significant differences
between cabozantinib and either sunitinib
(50 mg 4/2), pazopanib or tivozanib were
observed. However, it should be noted that this
NMA is underpowered with wide 95% CIs and
we cannot conclude ‘‘similar efficacy’’ as our
NMA was not an equivalence trial, which is a
common feature of all NMAs published so far.
Taken together, it is not possible to produce
a clear hierarchy of first-line TKIs based on sig-
nificant differences in efficacy. Consequently,
the toxicity of these TKIs may play a more sig-
nificant role in treatment decisions. The NMA
indicated that in terms of grade 3 and 4 AEs,
tivozanib had the most favourable safety profile
and was shown to be associated with signifi-
cantly less risk of toxicity than other TKIs. This
result was consistent with the high specificity of
tivozanib for VEGFR compared with other
multikinase inhibitors and the hypothesis that
fewer off-target side effects occur [3, 4].
A previous NMA of mRCC treatments did
not include safety profile data for all therapies
included [5]. To produce a comprehensive
analysis of approved first-line TKIs, unpublished
missing safety data were sought and obtained
from six studies. To this end, an updated value
from the internal tivozanib safety data bank for
the proportion of patients experiencing grade 3
or 4 AEs was also included (data on file). The
NMA was also computed using the Motzer et al.
Table 2 Network meta-analysis of PFS (left) and percentage grade 3 or 4 AEs (right): P score ranking
Efficacy Safety
Treatment P score Treatment P score
Cabozantinib 0.9481 Tivozanib 0.9261
Sunitinib (50 mg 4/2) 0.7411 Placebo 0.9021
Pazopanib 0.6914 Interferon-alfa 0.7659
Tivozanib 0.5988 Sunitinib (50 mg 2/1) 0.4889
Sunitinib (37.5 mg CDD) 0.4714 Pazopanib 0.4254
Sunitinib (50 mg 2/1) 0.4528 Sorafenib 0.3844
Sorafenib 0.3651 Cabozantinib 0.2367
Interferon-alfa 0.1930 Sunitinib (37.5 mg CDD) 0.1926
Placebo 0.0384 Sunitinib (50 mg 4/2) 0.1778
CDD continuous daily dose, PFS progression-free survival
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(2013) grade 3 or 4 AE data [22], and a similar
P score rank position was held by tivozanib
relative to other TKIs, but tivozanib ranked
lower than placebo and IFN-a, respectively (data
not shown).
A favourable safety profile has the direct
benefit to patient quality of life of experiencing
fewer side effects and may also be associated
with simplified management owing to fewer
dose interruptions or dose reductions that are
required to mitigate side effects [3]. Indeed, in
the tivozanib versus sorafenib RCT, tivozanib
was associated with significantly fewer dose
reductions and interruptions due to AEs than
sorafenib [22]. Furthermore, low toxicity is a
key characteristic of a therapy potentially suit-
able for use in combination therapy. The
CheckMate-016 trial demonstrated that the
combination of either sunitinib or pazopanib
with nivolumab, an anti-PD-1 antibody, resul-
ted in a high incidence of grade 3/4 AEs, making
neither combination suitable for use [31]. The
combinations of cabozantinib with nivolumab
and tivozanib with nivolumab are both under
investigation [32, 33]. Among these TKIs, our
safety data NMA results predict that tivozanib
has the greatest chance of being a suitable part-
ner to nivolumab, although the specific overlap
of each drug’s safety profile and any drug-drug
interaction will also have influence. As new
drugs enter the mRCC treatment landscape,
there will be even more combination therapy
options to pursue [4].
Cabozantinib had the greatest probability of
having the highest efficacy in the NMA; how-
ever, the cabozantinib RCT was conducted only
in intermediate or poor MSKCC risk patients;
hence, it is only indicated in these patients
[23, 34]. The NMA data support the ESMO and
EAU guidelines that include cabozantinib as a
TKI option in poor- or intermediate-risk
patients [1, 2].
The current EAU guideline recommends that
tivozanib is not used in first-line mRCC treat-
ment because the evidence is considered infe-
rior to other recommended TKIs [2]. This NMA
addresses this by providing indirect evidence to
supplement the direct evidence for tivozanib.
Specifically, the net heat plot diagram (Fig. 2d)
demonstrates that while the sorafenib-tivozanib
comparison strongly relies on the direct evi-
dence, the placebo-tivozanib network efficacy
estimate gains most evidence from indirect
comparisons. The NMA results show tivozanib
was not associated with significantly worse
efficacy compared with other first-line TKIs and
demonstrated a clearly reduced incidence of
grade 3 or 4 AEs. These data support the ESMO
guidelines, which recommend tivozanib as a
first-line mRCC treatment in favourable-risk
patients, alongside sunitinib and pazopanib,
and as a TKI option in intermediate-risk
patients, alongside cabozantinib, sunitinib and
pazopanib [1].
In addition, the efficacy NMA data showing
that sorafenib PFS is significantly different from
cabozantinib, and the P score ranking that
suggests sorafenib is less likely than either
alternative sunitinib regimen to be the best
treatment, which were themselves shown to be
not significantly different from placebo, provide
support for the guidelines that (1) no longer
recommend sorafenib as a first-line treatment,
apart from in limited-choice settings, and (2)
suggest that robust data to support the use of
alternative sunitinib dose regimens are lacking
[1, 2].
Limitations of meta-analyses using aggregate
data have been discussed previously [5]. As the
confidence intervals in our analysis and other
published NMAs [5, 36] are relatively wide,
results need to be treated with caution. In our
NMW we used a p\0.05 threshold to judge the
statistical significance of our findings, which
means that the results are statistically signifi-
cant if the confidence intervals do not include
the value of 1 (for HR and relative risk). The
forest plot for cabozantinib (Fig. 2c) with the HR
being[ 1 is indicative of inferior efficacy of all
other treatments compared with cabozantinib.
However, after including the uncertainty
around the point estimate (i.e., 95% CIs) for the
other TKIs, it becomes clear that the ‘‘true’’
effect could be better for cabozantinib (HR\ 1,
lower limit of the CI) or worse than cabozan-
tinib (HR[ 1, upper limit of the CI), which
then should be considered as being not statis-
tically significant. However, it has to be taken
into account that for cabozantinib only one
phase II trial (CABSUN Trial, N = 157) had been
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published [23]. The results of this trial remain
controversial and a number of concerns have
been raised because of the poor efficacy of
sunitinib in the control arm in which the
overall survival (OS) was found to be much
worse than in the majority of other studies [5].
On the other hand, tivozanib appeared to be the
TKI of choice in our NMA; however, the drug is
not approved in the USA because of poor OS
outcomes [22]. Finally, one can argue that grade
3–4 AEs may not entirely reflect treatment-re-
lated toxicity, suggesting that for an appropriate
interpretation of any NMA clinical context is
required. Although we have demonstrated no
statistically significant differences in the effi-
cacy of the TKIs approved as first-line therapy, it
does not rule out the possibility that there still
might be one when analysing another data set.
Specific to this NMA, it may be argued that
the omission of an evaluation of OS is a limi-
tation. In this regard it should be noted that
none of the currently approved TKIs for first-
line treatment of advanced or metastatic renal
cell cancers has shown a significant OS benefit
so far, which prompted us to omit an extensive
OS analysis. In addition, some other recently
published NMAs have provided evidence that
no single TKI treatment appeared to be superior
to its comparators for objective response rate
(ORR) and was not predictive of OS [36].
However, PFS has been shown to be predic-
tive of OS in TKI-treated patients and, although
strict surrogacy has not been established, the US
Food and Drug Administration has indicated
PFS end points are acceptable [37, 38]. Further-
more, OS can be impacted by differences in
sequential therapy, evidenced by the fact that
none of the studies included in this analysis
demonstrated a significant OS benefit over its
comparator; several of these studies suggest OS
results were possibly confounded by cross-over
to second-line therapies, and some studies
specifically evaluated cross-over in a switch
design [20–27, 30, 39–41]. Another possible
limitation is that grade 1 and 2 toxicities were
not included in the analysis. By definition,
higher grade AEs are more critical; however,
using the IFN-a safety profile as an example,
which includes mostly grade 1 and 2 AEs (re-
sulting in it ranking higher than all TKIs except
tivozanib by P score), side effects such as fatigue
are known to be challenging to manage [42].
Finally, the results of our NMA cannot be
directly applied to clinical practice because
cabozantinib is only approved for use in inter-
mediate or poor IMDC prognostic risk patients.
The cabozantinib trial is one of four trials (out
of 12) included in the NMA that had restrictive
prognostic risk group entry criteria. We inclu-
ded these studies to provide a comprehensive
analysis of all first-line approved TKIs because
there was an insufficient number of trials to
analyse them separately.
CONCLUSIONS
In this NMA no statistically significant differ-
ences in the efficacy among cabozantinib,
sunitinib, pazopanib and tivozanib could be
detected; however, tivozanib appeared to be
associated with a more favourable safety profile
in terms of grade 3 or 4 toxicities. The findings
of this NMA may bolster information from
pairwise comparisons to shape mRCC clinical
decision-making and to assist planning of
future RCTs.
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